(Reuters) - Gilead Sciences Inc signed deals with three Indian companies to drive sales and reduce manufacturing costs of low-cost generic versions of its HIV drug emtricitabine in developing countries.
Under deals with Ranbaxy Laboratories, Strides Arcolab and Mylan Inc's India unit, Gilead will provide technology and funding to help reduce manufacturing costs of the drug, the companies said.
Gilead, which sells the drug under the Emtriva brand, is the world's largest maker of branded drugs to treat the human immunodeficiency virus -- the cause of AIDS.
(Reporting by Shailesh Kuber; Editing by Viraj Nair)
Trending On Reuters
Sweatworking, the growing practice of meeting clients for a walk, a run or a fitness class, is elbowing networking out of bars and restaurants and into boutique fitness studios. Full Article
EU ministers discuss migrant crisis as shipwrecked bodies brought ashore Full Article
Lambert, Florida Georgia Line early winners at Country Music awards. Full Article